Indeed, although both SchS and VEXAS syndrome share autoinflammatory features, SchS generally responds well to IL‐1 inhibitors, whereas VEXAS syndrome may exhibit a less favorable response and even significant adverse reactions, making alternative cytokine‐targeted therapies preferable for its management.2, 3. The gene discussed is IL1B; the disease is VEXAS syndrome.